The antifibrotic effect of daclatasvir and sofosbuvir by downregulation of the tumor necrosis factor alpha (TNF‐α)/nuclear factor kappa B (NF‐κB) pathway [55] might have caused regression of liver fibrosis and contributed to the observed decrease in liver stiffness. This evidence concerns the gene NFKB1 and Hepatic fibrosis.